The White House’s sudden decision to withdraw Heidi Overton as President Trump’s pick to lead the Food and Drug Administration (FDA) has left the agency without a permanent chief for the foreseeable future, deepening a leadership vacuum that has persisted for over six months. The move, which caught senators and even Overton’s own team off guard, has raised fresh concerns about the stability of the agency responsible for overseeing the nation’s food and drug supply.
Sen. Bill Cassidy (R-La.), who chairs the Senate Health, Education, Labor and Pensions (HELP) Committee, expressed surprise at the withdrawal, noting that he had been in productive discussions with colleagues and believed Overton had sufficient support to advance out of committee. “The WH said that this was because she did not have the votes to pass. This was odd as I was having productive conversations with members,” Cassidy wrote on social media, signaling his frustration with the administration’s handling of the nomination.
Democratic senators were equally puzzled, though some, like Sen. Patty Murray (D-Wash.), had already pledged to oppose Overton due to her history of criticizing the abortion pill mifepristone. According to CNN, senior health officials were also blindsided, with Overton’s team learning of the withdrawal from media reports. The network cited sources familiar with the matter, indicating that Overton’s past clashes with Health and Human Services Secretary Robert F. Kennedy Jr. were a decisive factor, particularly after Stephen Miller—a supporter of the Make America Healthy Again (MAHA) movement—became White House chief of staff.
The FDA has been without a permanent leader since former Commissioner Marty Makary resigned in May. Deputy Commissioner for Food Kyle Diamantis has been serving as acting commissioner, but he has reportedly declined offers to take on the role permanently. This leadership gap comes at a critical time for the agency, which is navigating regulatory challenges in pharmaceuticals, food safety, and emerging technologies like artificial intelligence in drug development.
Chris Meekins, a healthcare policy analyst at Raymond James, said Overton’s withdrawal was not unexpected. “When Overton was selected in August, we warned her lack of management experience and ties to the Makary era could undermine efforts to stabilize FDA,” Meekins wrote, adding that his firm had given her less than a 50 percent chance of confirmation. He criticized the White House for ignoring warnings, saying, “The cost is lost time for an agency struggling to rebuild confidence among staff, patients, and industry.”
Outside the Senate, Overton faced intense opposition from groups concerned about her positions on mifepristone and flavored vapes. She had authored policy that relaxed standards for fruit-flavored vapes, which critics argue could appeal to young people. These controversies, combined with her lack of management experience, made her confirmation uncertain from the start.
The White House has not yet named a replacement, and Cassidy has indicated that the window for confirming a permanent commissioner this year has closed. “Unfortunately, with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats,” he wrote, a nod to the upcoming shift in Senate control. With Democrats set to take over the chamber, any new nominee will face a more challenging path, including a HELP Committee led by Sen. Bernie Sanders (I-Vt.).
Some reports suggest the White House is considering Sen. Roger Marshall (R-Kan.), who lost his reelection bid, as a potential pick. However, with Miller backing Kennedy, it remains unclear whether a more tempered nominee will emerge. The leadership vacuum is part of a broader pattern in the second Trump administration, with the Centers for Disease Control and Prevention (CDC) also having gone a year without a permanent director after the firing of Susan Monarez.
Former CDC Director Robert Redfield warned in an op-ed that an unstable FDA could cede U.S. biotech leadership to China. “Inconsistent, unstable FDA leadership jeopardizes the opportunity to reform the agency to advance cutting-edge therapies and stymies investment,” he wrote. The pharmaceutical industry echoed these concerns, with PhRMA spokesperson Chanse Jones stating, “A strong, science-driven FDA is essential to protecting patients and maintaining America’s leadership in biopharmaceutical innovation.” For now, the FDA remains rudderless, and the clock is ticking.
